Protocol Ledger

NCT04546620 · Phase II · ACTIVE NOT RECRUITING

Acalabrutinib in Combination With R-CHOP for Previously Untreated Diffuse Large B-cell Lymphoma (DLBCL)

Interventional Phase II clinical trial protocol NCT04546620 sponsored by University Hospital Southampton NHS Foundation Trust in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2021-10-19 Enrollment: 453 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT04546620
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)453 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04546620
Protocol FieldVerified Registry Value
NCT IdentifierNCT04546620
Consolidated Lead SponsorUniversity Hospital Southampton NHS Foundation Trust
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment453 participants (ESTIMATED)
Registered Start Date2021-10-19
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT04546620
Hospital Research SiteLocationSite Profile
Addenbrooke's HospitalCambridge, United KingdomOpen Hospital Dossier ->
Beatson West of Scotland Cancer CentreGlasgow, United KingdomOpen Hospital Dossier ->
Leicester Royal InfirmaryLeicester, United KingdomOpen Hospital Dossier ->
University College London HospitalLondon, United KingdomOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI